The clinical case of our patient is interesting for the extreme thrombocytosis, to the best of our knowledge never previously reported in the literature, and for its excellent response to treatment with the IL-1β receptor antagonist, suggesting a key pathogenic role of IL-1β in thrombocytosis as well as in the associated systemic symptoms of inflammation. This evidence concerns the gene IL1B and Thrombocytosis.